Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
A Prospective, Observational Study Comparing the Frequency of Treatment-Emergent Sexual Dysfunction Over 8 Weeks in Patients With Major Depressive Disorder Treated With Either Duloxetine Hydrochloride or a Selective Serotonin Reuptake Inhibitor Antidepressant and Evaluated Over 6 Months
Sponsor: Eli Lilly and Company
Listed as NCT00561509, this observational or N/A phase trial focuses on Major Depressive Disorder and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Sep 2025 — Nov 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abu Dhabi, United Arab Emirates , Bangkok, Thailand , Bat Yam, Israel , Beersheba, Israel , Beijing, China , Beirut, Lebanon , Cancún, Mexico , Dammam, Saudi Arabia , Dubai, United Arab Emirates , Guadalajara, Mexico and 47 more locations